Autopsy report · NCT01320683
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
Cause of deathSlow enrollment
“Slow accrual.”
Life of this trial
- Ran for about 3 years 9 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 1 year 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- City of Hope Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer
- Interventions
- oxaliplatin; leucovorin calcium; fluorouracil; bevacizumab; yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A; laboratory biomarker analysis
- Participants
- 1
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.